Pink Events | Breast Cancer Charity

Welcome to Pink Events Charity

Our Charity was founded by Sarah Pattinson (1966-2023) . Please follow the link to see the announcement, click here.

March 2024 – Pink Events were awarded Cancer Research’s Flame of Hope award for a second time. We first received the award in 2017 and are proud to be recognised again by Cancer Research UK, something which very few have ever achieved and so it is a great honour.

“On the 8th March Pink Events received the Flame Of Hope award from Cancer Research UK. The award is given to those who show an outstanding dedication to the cause. It’s great to receive the recognition for the work we do, having raised nearly £400,000 as a charity and passing our £100,000 milestone for Cancer Research in 2023.

I’m so proud of our family charity started by my amazing Auntie Sarah who would be so proud of this achievement, this award is dedicated to her and I know that she will be so proud of the legacy she gave to us.

Thank you to all our supporters and fundraisers, you’re vital to the work we do and all your efforts are appreciated beyond words, without you we wouldn’t be able to provide money to the causes that rely on us so heavily

“

James O’Rourke

Chair of Pink Events.

L to R – Lucy-Jayne, Steven, Mitchell & James at the award ceremony.

Please sponsor Lucy-Jayne in her fundraising run on 5th May. To see details and make a donation please click here

March 2024 – Pink Events have received a brief report from the Clinical Research Fellow, Ritika Rampal, who we have been sponsoring over the last two years. The summary report is as follows:

“My research focused on trying to manipulate a molecule (Mucin17) which is found in higher quantities in certain poor prognosis breast cancer cells. This molecule has shown to decrease the effectiveness of chemotherapy in these breast cancer types. My main aim for this project was to try to block the action of this molecule, so the breast cancer cells got more sensitive to chemotherapy treatment.

I have been using two different drugs, called talniflumate or GO-203, to block Mucin17. I’ve been testing these in combination with the chemotherapy agent epirubicin on two lines of cells growing in the laboratory that represent two different types of breast cancer, the triple negative breast cancers, and the estrogen receptor positive breast cancer cells. My results show that my new drugs decrease the amount of this molecule on breast cancer cells, and that using these drugs in combination with chemotherapy leads to an increased killing of cancer cells as compared to chemotherapy alone.

This combination also looked much more promising in the triple negative breast cancer cells, and it is this cancer type that often has the worst outcomes and most needs improved therapies. This means that with future research we can potentially decrease the amount of chemotherapy required for triple negative breast cancer patients, while killing as many cancer cells, but decreasing the overall side-effects for these patients.”

We would like to thank Ritika for her hard work and for keeping us informed, in lay terms, of the results of the work. Pink Events have now agreed with the Breast Care Unit to fund a further two year research project, the details of which are being worked on now. This confirms Pink Events commitment to finding ways to improve the outcomes of treatment for Breast Cancer patients.